Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

14 enrolled

Head & Neck

Head and Neck Neoplasms

NCT05526924 2026-03-04

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Phase 1 Recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07026474 2026-03-02

RePaIr-HN

Phase 3 Recruiting

214 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06557889 2026-02-11

REDUCE

Phase 2 Recruiting

86 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

128 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04004871 2025-12-11

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

60 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Completed

89 enrolled 14 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07158164 2025-11-13

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Phase 4 Recruiting

100 enrolled

BreastGastrointestinalHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms

NCT06699212 2025-10-15

ECLIPSE

Phase 3 Recruiting

412 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Phase 2 Recruiting

29 enrolled

Head & Neck

Head and Neck Neoplasms

NCT03340896 2025-09-02

SALTORL

Phase 3 Active not recruiting

256 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Laryngeal Diseases

NCT04356170 2025-09-02

TPFmORL

Phase 2 Completed

105 enrolled

Head & Neck

Head and Neck Neoplasms

NCT05446467 2025-08-20

Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC

Phase 2 Recruiting

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04675333 2025-08-03